Friday, September 23, 2016

Weekly Links September 23 , 2016



“MUST READ”
    • Key patents on the CRISPR technology were awarded to the Broad and Harvard University based on Zhang’s research developing a CRISPR system that edited mouse and human genes — many of them at the same time, Zhang and his team reported in a 2013 paper. The University of California is challenging those patents on behalf of UC Berkeley biochemist Jennifer Doudna and one of her key collaborators on a seminal 2012 paper, which described editing the test tube DNA using CRISPR.
  • www.nytimes.com
A Cautionary Tale of ‘Stem Cell Tourism’ The surgeon gasped when he opened up his patient and saw what was in his spine. It was a huge mass, filling the entire part of the man’s lower spinal column. “The entire thing was filled with bloody tissue, a…
The Parasite Underground When Vik was in his late 20s, blood started appearing in his stool. He found himself rushing to the bathroom as many as nine times a day, and he quit his job at a software company. He received a diagnosis of severe ulcerativ…
DISRUPTION, REVOLUTION
For biotech CEO Rachel Haurwitz, CRISPR is big business BERKELEY, Calif. — The question on the test was about CRISPR, but Rachel Haurwitz, then a graduate student at the University of California, Berkeley, botched it. She had never heard the term.
tags: Pocket weeklylinks
TOOLS/TECHNIQUES
    • The future of personalized medicine depends on affordable DNA sequencing. In the race for the $1,000 genome, several sequencer manufacturers are working on making equipment that can sequence DNA and RNA faster and more accurately. But so far, only one company – San Diego, California-based Illumina – has US FDA regulatory approval to use its sequencer in the clinic.
  • The Basics of Running a Chromatography Column - Bitesize Bio
    • Column chromatography is a common technique used to separate individual compounds from a mixture. You can use column chromatography on both a small or large scale to isolate and purify material for use on a later experiment.
If you are new to column chromatography or just want a refresher, then read on for a quick description of the basic process.
Explaining Genomics – No More Lies! In presenting simple explanations, are we setting ourselves up for a fall? “I have a confession to make. We’ve been lying to you.” Those were the words my school biology teacher (hello Mr. Boddington!) chose to op…
Get that Genotyping PCR to Work EVERY TIME Say you just joined a lab and have been assigned your very own project to work on. As part of your new responsibilities, you have to breed and maintain the mutant (or transgenic) mouse line which you will b…

HEALTH/MEDECINE
    • The Francis Crick Institiute in London, the biggest biomedical research institute in Europe, has officially opened its doors for research this week. Scientists have begun to move into the £650 million facility and are taking up residence in their new labs
Research at the Crick aims to discover how and why disease develops in order to find new ways to prevent, diagnose and treat conditions such as cancer, heart disease and stroke, infections and neurodegenerative conditions like motor neurone disease.
    • Some of the most promising advances in cancer research in recent years involve treatments known as immunotherapy. These advances are spurring billions of dollars in investment by drug companies, and are leading to hundreds of clinical trials. Here are answers to some basic questions about this complex and rapidly evolving field.
  • New clue to how lithium works in the brain
New clue to how lithium works in the brain Since the 1970s, U.S. doctors have prescribed lithium to treat patients with bipolar disorder. While the drug has a good success rate, scientists are still unsure exactly how it achieves its beneficial effe…
COMPANIES
    • The Palo Alto startup does this by offering up article extracts from published science papers using natural language processing. The Bioz platform helps researchers select products, plan experiments, write papers, apply for grants and collaborate, speeding up experimentation and drug discovery.
SOMETHING DIFFERENT
    • Winning isn’t everything.
So says the man who recently received $22 million after bringing to light multiyear accounting violations at Monsanto, the agribusiness and chemicals giant. Even though his is the second-largest award issued by the Securities and Exchange Commission under its five-year-old program to encourage whistle-blowers to come forward (after a $30 million award in September 2014), it feels, he told me, like something of a hollow victory.
Posted from Diigo. The rest of my favorite links are here.

No comments:

Post a Comment